• About
    • Login
    View Item 
    •   Institutional Repository Home
    • Vanderbilt University Medical Center
    • Department of Pathology, Microbiology & Immunology
    • Research reports
    • View Item
    •   Institutional Repository Home
    • Vanderbilt University Medical Center
    • Department of Pathology, Microbiology & Immunology
    • Research reports
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of Institutional RepositoryCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsDepartmentThis CollectionBy Issue DateAuthorsTitlesSubjectsDepartment

    My Account

    LoginRegister

    Expanding Hepatitis C Virus Care and Cure: National Experience Using a Clinical Pharmacist-Driven Model

    Koren, David E.
    Zuckerman, Autumn
    Teply, Robyn
    Nabulsi, Nadia A.
    Lee, Todd A.
    Martin, Michelle T.
    : http://hdl.handle.net/1803/15615
    : 2019-07

    Abstract

    Background. The US National Viral Hepatitis Action Plan depends on additional providers to expand hepatitis C virus (HCV) treatment capacity in order to achieve elimination goals. Clinical pharmacists manage treatment and medication within interdisciplinary teams. The study's objective was to determine sustained virologic response (SVR) rates for clinical pharmacist-delivered HCV therapy in an open medical system. Methods. Investigators conducted a multicenter retrospective cohort study of patients initiating direct-acting antivirals from January 1, 2014, through March 12, 2018. Data included demographics, comorbidities, treatment, and clinical outcomes. The primary outcome of SVR was determined for patients initiating (intent-to-treat) and those who completed (per-protocol) treatment. Chi-square tests were conducted to identify associations between SVR and adverse reactions, drug-drug interactions, and adherence. Results. A total of 1253 patients initiated treatment; 95 were lost to follow-up, and 24 discontinued therapy. SVR rates were 95.1% (1079/1134) per protocol and 86.1% (1079/1253) intent to treat. The mean age (SD) was 57.4 (10.1) years, the mean body mass index (SD) was 28.7 (6.2) kg/m(2), 63.9% were male, 53.7% were black, 40.3% were cirrhotic, 88.4% were genotype 1, and 81.6% were treatment-naive. Patients missing >= 1 dose had an SVR of 74.9%; full adherence yielded 90% (P < .0001). Conclusions. HCV treatment by clinical pharmacists in an open medical system resulted in high SVR rates comparable to realworld studies with specialists and nonspecialists. These findings demonstrate the success of a clinical pharmacist-delivered method for HCV treatment expansion and elimination.
    Show full item record

    Files in this item

    Icon
    Name:
    Expanding Hepatitis C Virus Care ...
    Size:
    270.9Kb
    Format:
    PDF
    View/Open

    This item appears in the following collection(s):

    • Research reports

    Connect with Vanderbilt Libraries

    Your Vanderbilt

    • Alumni
    • Current Students
    • Faculty & Staff
    • International Students
    • Media
    • Parents & Family
    • Prospective Students
    • Researchers
    • Sports Fans
    • Visitors & Neighbors

    Support the Jean and Alexander Heard Libraries

    Support the Library...Give Now

    Gifts to the Libraries support the learning and research needs of the entire Vanderbilt community. Learn more about giving to the Libraries.

    Become a Friend of the Libraries

    Quick Links

    • Hours
    • About
    • Employment
    • Staff Directory
    • Accessibility Services
    • Contact
    • Vanderbilt Home
    • Privacy Policy